Our Pricing

Semaglutide or Tirzepatide Private Prescription UK

Securing a semaglutide or tirzepatide private prescription UK has become straightforward with regulated online pharmacies. At Cured Pharmacy, our UK-registered clinical team provides free consultations under three minutes, prescribing genuine licensed Mounjaro (tirzepatide) from £135.00 and Wegovy (semaglutide) with transparent pricing and discreet next-day delivery across the UK.

Understanding Semaglutide and Tirzepatide for Weight Loss

Semaglutide and tirzepatide represent the latest generation of GLP-1 receptor agonists licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities [1]. Both medications work by mimicking natural gut hormones that regulate appetite and blood glucose levels, though their mechanisms differ significantly.

Tirzepatide, marketed as Mounjaro, is the UK's first dual GIP/GLP-1 receptor agonist, activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways [2]. This dual action produces more pronounced metabolic effects than semaglutide alone. In the SURMOUNT-1 trial, participants taking the highest tirzepatide dose achieved an average 22.5% body weight reduction over 72 weeks [2].

Semaglutide, available as Wegovy in the UK, works through single GLP-1 receptor activation. The STEP 1 trial demonstrated an average 14.9% weight loss over 68 weeks at the 2.4mg maintenance dose [3]. Both medications require once-weekly subcutaneous injection and are prescription-only medicines requiring clinical assessment by a UK prescriber before dispensing.

Comparing Semaglutide or Tirzepatide Private Prescription UK Options

When choosing between semaglutide or tirzepatide for your private prescription, several clinical factors guide the decision. Tirzepatide generally produces greater weight loss in head-to-head comparisons, though individual response varies considerably based on metabolic profile, adherence, and lifestyle modifications [4].

Your UK prescriber will assess your medical history, current medications, BMI, and weight-related health conditions during consultation. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Both medications carry similar side effect profiles, predominantly gastrointestinal symptoms that typically diminish after the initial titration period [1][3].

Dosing Schedules and Titration

Wegovy (semaglutide) follows a structured four-month titration: starting at 0.25mg weekly, increasing monthly through 0.5mg, 1mg, and 1.7mg, before reaching the 2.4mg maintenance dose [3]. Mounjaro (tirzepatide) begins at 2.5mg weekly, with optional increases every four weeks up to a maximum 15mg dose depending on tolerability and response [2]. The gradual dose escalation minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's metabolic effects.

How to Obtain Your Private Prescription Through Cured Pharmacy

Our streamlined process ensures you can access semaglutide or tirzepatide private prescription UK services without visiting a GP surgery. After completing a comprehensive online medical questionnaire covering your weight history, current health conditions, and medications, a UK-registered prescriber reviews your assessment typically within hours.

If clinically appropriate, your prescriber issues a private prescription which our GPhC-registered pharmacy (9012511) dispenses with genuine UK-licensed medication. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical governance, ensuring every prescription meets MHRA standards. We provide discreet packaging and next-day delivery across the UK, with ongoing prescriber support throughout your treatment journey.

Transparent Pricing Before Consultation

Unlike many private services, Cured Pharmacy displays exact pricing before you begin consultation. Our commitment to transparency means no hidden fees or surprise charges after your clinical assessment. The consultation itself is completely free, and you only pay for medication if your prescriber determines treatment is suitable and you choose to proceed.

Clinical Efficacy: What the Trials Show

The evidence base for both medications is substantial. The STEP programme evaluated semaglutide 2.4mg across multiple trials involving over 4,500 participants. STEP 1 demonstrated that 86.4% of participants achieved at least 5% weight loss, with 69.1% losing 10% or more of their baseline body weight [3]. Participants also showed improvements in cardiovascular risk markers including blood pressure, lipid profiles, and glycaemic control.

Tirzepatide's SURMOUNT trials enrolled over 6,500 participants across different populations. In SURMOUNT-1, the 15mg dose produced average weight reductions of 22.5%, with 57% of participants achieving at least 20% weight loss [2]. SURMOUNT-2 specifically examined participants with type 2 diabetes, demonstrating both glycaemic and weight management benefits. Both medication classes show sustained efficacy when combined with reduced-calorie diet and increased physical activity [4].

Long-term data increasingly demonstrates that these medications address the biological drivers of obesity rather than simply suppressing appetite temporarily. Neuroimaging studies reveal altered brain responses to food cues, whilst metabolic studies show improved insulin sensitivity and reduced hepatic fat accumulation [5]. These mechanisms explain why weight loss tends to plateau around 60-72 weeks rather than continuing indefinitely.

Managing Side Effects and Treatment Expectations

Gastrointestinal symptoms represent the most common side effects for both semaglutide and tirzepatide, affecting 40-50% of users during initial titration [1][2]. Nausea, occasional vomiting, diarrhoea, and constipation typically peak during the first 8-12 weeks before subsiding as your body adapts. Taking medication with food, eating smaller portions, and avoiding high-fat meals significantly reduces these effects.

Rare but serious side effects require immediate medical attention: persistent severe abdominal pain may indicate pancreatitis, whilst changes in vision, persistent nausea, or signs of thyroid swelling warrant urgent prescriber contact [3]. Your UK prescriber will review your complete medical history to identify any contraindications before prescribing. Regular follow-up consultations, typically every 12 weeks, monitor your progress and adjust dosing as needed.

Realistic expectations are crucial for treatment success. These medications are not quick fixes but tools supporting comprehensive lifestyle modification. Clinical trials showing impressive weight loss percentages all included structured dietary counselling and physical activity programmes [4]. Your prescriber may recommend combining treatment with registered dietitian support or behavioural therapy for optimal outcomes.

When to Contact Your Prescriber

Reach out if you experience severe or persistent side effects, notice no weight loss after 12 weeks at maintenance dose, develop signs of allergic reaction, or have concerns about continuing treatment. Our clinical team at Cured Pharmacy remains available throughout your treatment journey, with prescriber support accessible via phone on (+44) 116 4646009 during business hours.

Alternative Weight Loss Treatments Available

Whilst semaglutide and tirzepatide represent the most effective pharmacological options currently available, alternative treatments suit different clinical scenarios. Saxenda (liraglutide) is an earlier GLP-1 agonist requiring daily rather than weekly injection, producing average weight loss of 8-9% in clinical trials [6]. The more frequent dosing schedule may suit patients who prefer gradual daily medication over weekly injections.

Orlistat-based treatments including Xenical, Orlos, and Alli work through an entirely different mechanism, blocking approximately 30% of dietary fat absorption in the intestines [7]. These medications suit patients who cannot tolerate GLP-1 agonists or prefer oral capsules to injections. Clinical trials show average weight loss of 5-10% when combined with a reduced-calorie, lower-fat diet [7]. Gastrointestinal side effects differ from GLP-1 medications, primarily involving oily stools and urgency when consuming high-fat meals.

Your prescriber will discuss all suitable options during consultation, considering your medical history, lifestyle preferences, previous weight loss attempts, and treatment goals. Some patients begin with oral medications before progressing to injectables, whilst others require combination approaches addressing multiple metabolic pathways. The goal is finding the most effective, sustainable treatment for your individual circumstances.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Wegovy 2.4 mg solution for injection in pre-filled pen. MHRA. https://products.mhra.gov.uk/
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
5. van Bloemendaal, L., IJzerman, R. G., Ten Kulve, J. S., et al. (2014). GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes, 63(12), 4186–4196. https://doi.org/10.2337/db14-0849
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
7. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment combined with lifestyle modifications including diet and exercise.